This file contains CAS Registry Numbers for easy and accurate substance identification.


=> Uploading C:\STNEXP4\QUERIES\714a.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 19:12:26 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -708 TO ITERATE

100.0% PROCESSED 708 ITERATIONS

SEARCH TIME: 00.00.01

L22 SEA SSS FUL L1

7 L2

=> d 1-7 ibib abs hitstr

ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:707131 CAPLUS

DOCUMENT NUMBER: 133:267154

TITLE: Preparation of nitrogen mustard compounds and prodrugs INVENTOR(S):

Springer, Caroline Joy; Davies, Lawrence Christopher

2 ANSWERS

PATENT ASSIGNEE(S): Cancer Research Campaign Technology Limited, UK

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
KIND DATE
                                          APPLICATION NO. DATE
     PATENT NO.
                     _ _ _ _
                      A1
                            20001005
                                           WO 2000-GB1194
                                                            20000329
     WO 2000058271
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                      A5
                            20001016
                                          AU 2000-39746
                                                            20000329
     AU 2000039746
     NZ 513759
                            20010928
                                           NZ 2000-513759
                                                            20000329
                       Α
     EP 1165493
                            20020102
                                           EP 2000-918981
                                                            20000329
                       A1
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
                                           JP 2000-607975
                                                            20000329
     JP 2002540186
                       T2
                            20021126
PRIORITY APPLN. INFO.:
                                        GB 1999-7414 A 19990331
                                        WO 2000-GB1194
                                                         W 20000329
```

OTHER SOURCE(S): MARPAT 133:267154

Ι

AB Nitrogen mustard compds. and prodrugs I [R = OH or NHCH(Z)CO2R7, resp., where R1, R2 = C1, Br, I, OSO2Me, or OSO2Ph; R1a, R2a, R1b, R2b = H, C1-4-alkyl or -haloalkyl; R3 = F, Cl, Br, I, OCHF2, C.tplbond.CH, OCF3, Me, CF3, SF5, SCF3, or CF2CF3; R4 = H, any group given for R3; R5 = H, F; R7 = H, Me3C, allyl; Z = (un)substituted -CH2-T-W, where <math>T = CH2, O, S, S(0), or SO2; W = CO2H, CONH2, SO2NH2, SO3H, PO3H2, tetrazol-5-yl, heterocyclylthio, etc. (with provisos)] were prepared for use in therapy and treatment, for example, of cancer. Thus, [3,5-difluoro-4-[bis(2iodoethyl)amino]benzoyl]-L-glutamic acid, prepared via amidation of 3,5-difluoro-4-[bis(2-iodoethyl)amino]benzoic acid with di-tert-butyl-L-glutamate hydrochloride, showed antitumor activity against breast carcinoma in mice at 0.98 mM vs. 2.9 mM for the prior art compound [3-fluoro-4-[bis(2-chloroethyl)amino]benzoyl]-L-glutamic acid. IT 298211-31-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of nitrogen mustard compds. and prodrugs)

RN 298211-31-1 CAPLUS

CN Benzoic acid, 4-[bis(2-bromopropyl)amino]-3,5-difluoro- (9CI) (CA INDEX NAME)

ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1979:167816 CAPLUS

90:167816 DOCUMENT NUMBER:

Some physicochemical properties and reactivity of TITLE:

p-[bis(2-chloroalkyl)amino]phenylalkanoic acids Karpavicius, K.; Juodvirsis, A.; Prasmickiene, G.; AUTHOR (S):

Knunyants, I. L.

Inst. Elementoorg. Soedin., Moscow, USSR CORPORATE SOURCE:

Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya SOURCE:

(1979), (1), 51-8

CODEN: IASKA6; ISSN: 0002-3353

Journal DOCUMENT TYPE: Russian LANGUAGE:

> In p-(ClCHRCH2) 2NC6H4 (CH2) nCO2H (I; R = H, Me; n = 0-3) the cytotoxic amino groups exhibit an appreciable electron-donating effect, whereas the carboxyalkyl groups show a weaker effect. The CH2 protons in the amino group of I (R = H; n = 1-3) are magnetically equivalent; those in I (R = H; n= 0) and the analogous cinnamic acid derivs. are not. The hydrolysis of C-Cl in I appears to be 1st order; that of I (R = Me) is an order of magnitude faster than that of I (R = H).

ΙT 5379-46-4

RL: PRP (Properties)

(NMR of)

RN5379-46-4 CAPLUS

Benzoic acid, 4-[bis(2-chloropropyl)amino]- (9CI) (CA INDEX NAME) CN

ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1978:58444 CAPLUS

DOCUMENT NUMBER: 88:58444

Physicochemical properties and antileukemia activity TITLE:

of some p-[bis(2-chloropropyl)amino] - and

p-[bis(2-chloroethyl)amino]phenylalkanoic acid

derivatives

AUTHOR (S): Karpavicius, K.; Prasmickiene, G.; Juodvirsis, A.;

Ivanova, L. E.; Khomchenovskii, E. I.

CORPORATE SOURCE: Inst. Biokhim., Vilnius, USSR SOURCE:

Poiski Izuch. Protivoopukholevykh,

Protivovospalitel'nykh Mutagennykh Veshchestv (1977), 66-75. Editor(s): Kanopkaite, S. Akad. Nauk Lit.

SSR, Inst. Biokhim.: Vilnius, USSR.

CODEN: 37BOA3

DOCUMENT TYPE: Conference LANGUAGE: Russian

GI

$$R_2N$$
 — (CH₂) $_n$ CO₂H

of 8 p-[bis(2-chloroalkyl)amino]phenylalknoic acids (I) were presented. The 2-chloropropyl derivs. had a greater reactive capacity than did the 2-chloroethyl derivs. owing to the presence of the electron-donor Me group. The 2-chloropropyl derivs. were also generally more toxic than the 2-chloroethyl groups. The 2-chloropropyl derivs were effective against granulocytopoiesis and on transplanted leukemias Nk/Ly and L-1210 in mice, whereas the 2-chloroethyl derivs. were effective against lymphopoiesis and development of Shchvetz leukemia in rats.

IT 5379-46-4

RL: BIOL (Biological study)

(antileukemic activity and physicochem. properties of)

RN 5379-46-4 CAPLUS

Benzoic acid, 4-[bis(2-chloropropyl)amino]- (9CI) CN (CA INDEX NAME)

ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1978:15944 CAPLUS

DOCUMENT NUMBER:

88:15944

TITLE:

Comparative study of the general toxicity and

antileukemic activity of new phenylalkanoic acid

derivatives under experimental conditions

AUTHOR (S):

Ivanova, L. E.; Zaretskii, I. I.; Khomchenovskii, E.

I.; Karpavicius, K.; Prasmickiens, G.

CORPORATE SOURCE:

Moscow, USSR

Leikozologiya (1975), 4, 23-9

CODEN: LEIKDK

Journal

DOCUMENT TYPE:

LANGUAGE: Russian

GI

SOURCE:

$$(C1CH_2CH_2)_mN$$
 $(CH_2)_nCO_2H$

AB The toxicity and antileukemic effects of 8 phenylalkanoic acids (I) were determined The 2-chloropropyl derivs., p-di(2-chloropropyl)aminobenzoic acid [5379-46-4], p-di(2-dichloropropyl)aminophenylacetic acid [19521-09-6], p-di-(2-chloropropyl)aminophenylpropionic acid [22812-54-0], and p-di(2-chloropropyl) aminophenylbutyric acid [55774-31-7] had greater antileukemic effects than the resp. 2-chloroethyl derivs. although LD50 values tended to be lower.

ΙT 5379-46-4

> RL: BIOL (Biological study) (leukemia inhibition by)

RN5379-46-4 CAPLUS

CN Benzoic acid, 4-[bis(2-chloropropyl)amino]- (9CI) (CA INDEX NAME)

Ι

$$\begin{array}{c|c} & \text{C1} & \text{C1} \\ \text{C1} & \text{CH}_2\text{-CH-Me} \\ \text{Me-CH-CH}_2\text{-N} & \text{CO}_2\text{H} \end{array}$$

AUTHOR (S):

ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1969:430178 CAPLUS

DOCUMENT NUMBER: 71:30178

Synthesis and study of the reactivity of TITLE:

> p-[bis(2-chloropropyl)amino]phenylalkanoic acids Prasmickiene, G.; Sukeliene, D.; Karpavicius, K.;

Kil'disheva, O. V.

CORPORATE SOURCE: Nauch.-Issled. Inst. Onkol., Vilnius, USSR

SOURCE:

Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya

(1969), (3), 643-6

CODEN: IASKA6; ISSN: 0002-3353

DOCUMENT TYPE: Journal LANGUAGE: Russian

To 2.2 ml. POCl3 in Me2NCHO was added 5.72 g. p-(ClCHMeCH2)2NC6H4NH2 in the same solvent and the mixture kept 1 day at 40° to give

p-(ClCH-MeCH2)2NC6H4CHO, (I), m. 104-6°. I with N2H4 gave the appropriate ylidenehyrazine, m. 167-9°, while HONH2 gave the oxime,

m. 125-7°, which after 3 hrs. reflux in Ac20 gave 71%

p-(ClCHMeCH2)2NC6H4CN, m. 128-30°, which heated in concentrated H2SO4 2

hrs. at 50° gave the corresponding amide, m. 138-40°. Oxidation of the aldehyde or heating the benzamide with HCl gave

p-(ClCHMeCH2)2NC6H4CO2H, m. 160-2°. Propylene oxide added to

p-H2NC6H4CH2CH2CONH2 in 30% AcOH gave, in 1 day, 77%

(HOCHMeCH2) 2NC6H4CH2CH2CONH2, m. 102-4°, which, heated with POCl3 1 hr., gave, on quenching in ice, 73% p-(ClCHMeCH2)2NC6H4CH2CH2CN (II), m.

66-8°, which in concentrated H2SO4 2 hrs. at 50° gave the

corresponding amide, m. 58-60°. I heated with malonic acid in pyridine-piperidine 3 hrs. gave 76% p-(ClCHMeCH2)2NC6H4CH:CHCO2H (III), m.

131-3°. II heated with concentrated HCl gave 59% corresponding free

acid, m. 69-71°, also formed by hydrogenation of III over PdCaCO3.

IT 5379-46-4P

> RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN5379-46-4 CAPLUS

CN Benzoic acid, 4-[bis(2-chloropropyl)amino]- (9CI) (CA INDEX NAME)

ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1966:84288 CAPLUS

DOCUMENT NUMBER: 64:84288 ORIGINAL REFERENCE NO.: 64:15785d-q

TITLE: Tumor chemotherapy. XXX. Studies on the

hexamethylenetetramine salt of p-bis(2chloroethyl) amino-ω-bromoacetophenone

AUTHOR (S): Jen, Yun-Feng; Kao, I-Sheng CORPORATE SOURCE: Inst. Mater. Med., Acad. Sinica, Shanghai, Peop. Rep.

China

SOURCE: Huaxue Xuebao (1965), 31(6), 486-92,500

CODEN: HHHPA4; ISSN: 0567-7351

DOCUMENT TYPE: Journal LANGUAGE: Chinese

cf. CA 63, 17000b. p-(XRCHCH2) 2NC6H4COCH2[(CH2)6N4]+Br-(Ia)(X = Br, R =H) (I), (X = I, R = H) (II), p-EtO2CNHC6H4COCH2[(CH2)6N4]+Br- (III), and p-EtO2CNHC6H4COCH2SC(:NH2+Br-)NH2 (IV), the analogs of the antitumor compound AT-584, were prepared The starting materials for the synthesis of I and II were p-bis[2-haloethyl (and propyl)] aminobenzoic acids (V and VI), resp. VI was synthesized by 2 methods: (1) [R(HO)CHCH2]2NC6H4CO2Et-p was first halogenated with PBr3 or POCl3 and then hydrolyzed with HCl or HBr to yield p-bis[2-chloropropyl (and 2-bromoethyl)] aminobenzoic acids. Chlorination of p-bis(2-hydroxypropyl)aminobenzene with POCl3 in dimethylformamide gave p-bis(2-chloropropyl)aminobenzaldehyde, which was treated with KMnO4 in acetone to afford VI. The 2nd route gave a better yield. V and VI in benzene reacted sep. with SOCl2 to give the acid chlorides, which were treated sep. with diazomethane to yield the diazoacetophenones (VII). VII were decomposed in dioxane with HBr to form bromoacetophenone derivs., which treated with hexamethylenetetramine in chloroform gave I and II, resp. p-Aminoacetophenone was treated with ethyl chloroformate in the presence of triethylamine as the condensing agent to form p-ethoxycarbonyliminoacetophenone (VIII). When N,N-diethylaniline was used as the condensing agent instead of triethylamine, the yield was better. VIII was first brominated in acetic acid with Br and then treated with hexamethylenetetramine or thiourea to afford III and IV, resp. Preliminary pharmacol. examns. showed that I and II were as active as AT-584 against HeLa cells in culture medium, while III and IV were less active.

IT 5379-46-4, Benzoic acid, p-[bis(2-chloropropyl)amino]-

(preparation of) 5379-46-4 CAPLUS

RN

CN Benzoic acid, 4-[bis(2-chloropropyl)amino]- (9CI) (CA INDEX NAME)

ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1951:863 CAPLUS

DOCUMENT NUMBER: 45:863

ORIGINAL REFERENCE NO.: 45:139h-i,140a-g

TITLE: Aryl-2-haloalkylamines. VII. Some derivatives of

2-naphthyldi(2-haloalkylamines)

AUTHOR(S): Davis, W.; Everett, J. L.; Ross, W. C. J.

CORPORATE SOURCE: Roy. Cancer Hosp., London

SOURCE: Journal of the Chemical Society, Abstracts (1950)

1331-7

CODEN: JCSAAZ; ISSN: 0590-9791

DOCUMENT TYPE: Journal LANGUAGE: Unavailable

AB cf. C.A. 44, 6838i. This work is a continuation of that in C.A. 43, 7442g, and 44, 1431e, in which it was shown that many arylbis(2-haloalkyl)amines inhibited the growth of various animal tumors and of spontaneous and transmitted leukemia in the Furth AK 1 pure line; 2-C10H7N(CH2CH2Cl)2 has been used clinically for the treatment of various lymphadenopathies in human patients with encouraging results. 1,7-AcCl0H6NH2 (16 g.), added to 11.2 g. NaOH and 18.4 g. 50% N2H4.H2O in 175 g. (HOC2H4)2O and heated 3 hrs. at 195°, gives 14.5 g.

1,7-EtC10H6NH2, brown oil (Ac derivative, m. 167°). 1,2;3,4-Tetrahydronaphthalene (264 g.), nitrated according to Schroeter (C.A. 16, 1673), gives 60 g. 5-NO2 and 45 g. 6-NO2 derivs.; catalytic reduction (Raney Ni) gives 5,6,7,8-tetrahydro-1- and -2-naphthylamines. 1-Keto-1,2,3,4-tetrahydronaphthalene oxime, reduced with Na in EtOH, gives 1,2,3,4-tetrahydro-1-naphthylamine, b10 114°. These amines were converted into the N,N-bis(2-hydroxyethyl) derivs. in the usual manner but it is preferable to use SOCl2 in CHCl3 for the chlorination stage, N, N-Bis (2-chloroethyl) -2-methyl-1-naphthylamine, oil. 1,2,3,4-Tetrahydro-N,N-bis(2-hydroxyethyl)-1-naphthylamine, m. 89° (picrate, m. 140°); N,N-bis-(2-chloroethyl)-1,2,3,4-tetrahydro-1naphthylamine-HCl, m. 158°. 5,6,7,8-Tetrahydro-N,N-bis(2hydroxyethyl)-1-naphthylamine picrate, m. 199° (decomposition); N, N-bis (2-chloroethyl) -5,6,7,8-tetrahydro-1-naphthylamine, an oil (picrate, m. 121°). N-(2-Naphthyl)-N-methyl-2-hydroxyethylamine picrate, m. 160°; N-(2-naphthyl)-N-methyl-2-chloroethylamine, m. 52.5° (inactive); N-(2-naphthyl)-N-methyl-2-hydroxypropylamine picrate, m. 154°; N-(2-naphthyl)-N-methyl-2-chloropropylamine, m. 64° (inactive). N, N-bis(2-hydroxyethyl)-6-methyl-2-naphthylamine, m. 94°; N,N-bis(2-chloroethyl)-6-methyl-2-naphthylamine, m. 65°; bis(2-bromoethyl) analog, m. 88°; bis(2-iodoethyl) analog, m. 100-1°. N, N-Bis(2-chloroethyl)-8-methyl-2naphthylamine, m. 63°; 8-Et homolog, m. 48°; bis(2-bromoethyl)-8-ethyl analog, m. 57°; bis(2-iodoethyl) analog, m. 85°. 8-Acetyl-N,N-bis(2-hydroxyethyl)-2-naphthylamine, yellow, m. 113°; bis(2-chloroethyl) analog, yellow, m. 84°; bis(2-bromoethyl) analog, yellow, m. 94.5° (solns. of the last 2 compds. exhibit an intense yellow-green fluorescence). N-(2-Chloroethyl)-1,2,3,4-tetrahydro-2-naphthylamine-HCl, m. 215°; picrate, m. 197°. N,N-Bis(2-chloroethyl)-1,2,3,4-tetrahydro-2-naphthylamine-HCl, m. 164°; bis(2-bromoethyl) analog-HBr, m. 229°. 5,6,7,8-Tetrahydro-N,N-bis(2-hydroxyethyl)-2-naphthylamine, m. 57°; bis(2-chloroethyl) analog, m. 65°, photoluminescent. N, N-Bis (2-hydroxyethyl) -2-phenanthrylamine, m. 155°; bis-(2-chloroethyl) analog, m. 91-2°; bis(2-bromoethyl) analog, m. 111-12°; bis(2-iodoethyl) analog, m. 117°. N, N-Bis (2-hydroxyethyl) -3-phenanthrylamine, m. 109-10°; bis(2-chloroethyl) analog, m. 73°; bis(2-bromoethyl) analog, m. 98°; bis(2-iodoethyl) analog, m. 125°. 2-(2-Hydroxyethylamino)fluorene, yellow, m. 150° (cf. C.A. 43, 7442g); 2-chloroethyl analog, m. 127°. 2-[Bis(2-bromoethyl)amino]fluorene m. 137°. N'-Propionyl-N, N-bis(2-chloroethyl)-p-phenylenediamine m. 101-3°. p-[Bis(2-chloropropyl)amino]benzoic acid, m. 165-6°; Me ester, m. 61°. p-MeOC6H4N(CH2CH2Cl)2 (2.5 g.) and 3.4 g. Et2NCS2Na in 200 ml. 50% aqueous Me2CO, refluxed 2 hrs., give N, N-bis[2-(diethyldithiocarbamyl)ethyl]-p-anisidine, m. 85-6°. p-MeOC6H4[NCH2CH(OH)CH2Cl]2 (40 g.) in 500 ml. boiling ether, gradually treated with 40 g. KOH, gives N, N-bis(2, 3-epoxypropyl)-p-anisidine, yellow, b9 228-9°; this is inactive. Data are given for the rate of hydrolysis of a number of these compds. in 50% aqueous Me2CO at 66°. The effect of various substituents is discussed. There is the expected increase in the rate of hydrolysis on passing from the Cl to Br compound but a somewhat surprising decrease for the iodides. 5379-46-4, Benzoic acid, p-[bis(2-chloropropyl)amino]-(preparation of) 5379-46-4 CAPLUS Benzoic acid, 4-[bis(2-chloropropyl)amino]- (9CI) (CA INDEX NAME)

$$C1$$
 $CH_2-CH-Me$
 $Me-CH-CH_2-N$
 CO_2H

IT

RN

CN


Uploading 714.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1



Structure attributes must be viewed using STN Express query preparation.

=> s 11

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 10:55:44 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -2 TO ITERATE

100.0% PROCESSED

SEARCH TIME: 00.00.02

2 ITERATIONS

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE** BATCH **COMPLETE**

PROJECTED ITERATIONS: 2 TO

PROJECTED ANSWERS:

124 0 TO

0 SEA SSS SAM L1

L3 0 L2

=> s l1 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 10:55:52 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -40 TO ITERATE

100.0% PROCESSED **40 ITERATIONS**

1 ANSWERS

SEARCH TIME: 00.00.02

1 SEA SSS FUL L1

L5 1 L4

. ..

=> d ibib abs hitstr

ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:707131 CAPLUS

DOCUMENT NUMBER: 133:267154

TITLE:

Preparation of nitrogen mustard compounds and prodrugs INVENTOR (S): Springer, Caroline Joy; Davies, Lawrence Christopher

PATENT ASSIGNEE(S): Cancer Research Campaign Technology Limited, UK

PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
PATENT NO.
                         KIND DATE
                                                 APPLICATION NO.
                                                                    DATE
                                -----
                                                  -----
      WO 2000058271
                          A1
                                20001005
                                                 WO 2000-GB1194
                                                                     20000329
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
               CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
               ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
               SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
               ZW, AM, AZ, BY, KG, KZ, MD,
                                              RU, TJ, TM
          RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
               CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      NZ 513759
                                20010928
                                                 NZ 2000-513759
                                                                    20000329
      EP 1165493
                          A1
                                20020102
                                                 EP 2000-918981
                                                                     20000329
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO
      JP 2002540186
                                20021126
                                                 JP 2000-607975
                                                                     20000329
PRIORITY APPLN. INFO.:
                                              GB 1999-7414
                                                                 Α
                                                                    19990331
                                              WO 2000-GB1194
                                                                 W
                                                                    20000329
OTHER SOURCE(S):
                            MARPAT 133:267154
GI
```

Nitrogen mustard compds. and prodrugs I [R = OH or NHCH(Z)CO2R7, resp., AΒ where R1, R2 = C1, Br, I, OSO2Me, or OSO2Ph; R1a, R2a, R1b, R2b = H,

I

C1-4-alkyl or -haloalkyl; R3 = F, Cl, Br, I, OCHF2, C.tplbond.CH, OCF3, Me, CF3, SF5, SCF3, or CF2CF3; R4 = H, any group given for R3; R5 = H, F; R7 = H, Me3C, allyl; Z = (un)substituted -CH2-T-W, where T = CH2, O, S, S(O), or SO2; W = CO2H, CONH2, SO2NH2, SO3H, PO3H2, tetrazol-5-yl, heterocyclylthio, etc. (with provisos)] were prepd. for use in therapy and treatment, for example, of cancer. Thus, [3,5-difluoro-4-[bis(2-iodoethyl)amino]benzoyl]-L-glutamic acid, prepd. via amidation of 3,5-difluoro-4-[bis(2-iodoethyl)amino]benzoic acid with di-tert-butyl-L-glutamate hydrochloride, showed antitumor activity against breast carcinoma in mice at 0.98 mM vs. 2.9 mM for the prior art compd. [3-fluoro-4-[bis(2-chloroethyl)amino]benzoyl]-L-glutamic acid. 298211-06-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nitrogen mustard compds. and prodrugs)

RN 298211-06-0 CAPLUS CN L-Glutamic acid, N-

IT

L-Glutamic acid, N-[4-[bis(2-bromopropyl)amino]-3,5-difluorobenzoyl](9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

1/1

